Zynex, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US98986M1036
USD
1.03
-0.14 (-11.97%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Zynex, Inc. stock-summary
stock-summary
Zynex, Inc.
Pharmaceuticals & Biotechnology
Zynex, Inc. manufactures and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The Company operates through medical devices segment, which include electrotherapy and pain management products. The Company conducts its business through its subsidiaries and the operating subsidiary is Zynex Medical, Inc. (ZMI). The Company’s devices are intended for pain management to reduce reliance on drugs and provide rehabilitation and mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current (IFC), neuromuscular electrical stimulation (NMES) and transcutaneous electrical nerve stimulation (TENS). The Company's devices are small, portable, battery-operated and include an electrical pulse generator that is connected to the body via electrodes.
Company Coordinates stock-summary
Company Details
9555 MAROON CIRCLE , ENGLEWOOD CO : 80112
stock-summary
Tel: 1 303 86739041 800 4956670
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 39 Schemes (19.79%)

Foreign Institutions

Held by 55 Foreign Institutions (4.28%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Thomas Sandgaard
Chairman of the Board, President, Chief Executive Officer
Mr. Michael Cress
Independent Director
Mr. Joshua Disbrow
Independent Director
Mr. Barry Michaels
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
22 Million
(Quarterly Results - Jun 2025)
Net Profit:
-20 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 46 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

36.51

stock-summary
Return on Equity

-2,272.96%

stock-summary
Price to Book

36.52